Reply

**to the Comment of Wozel et al. on the Paper by Mochida et al.
(Chemotherapy 1998;44:36–41)**

T. Matsumoto^a O. Mochida^b

^aDepartment of Urology, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, and ^bDepartment of Urology, Hamanomachi Hospital, Fukuoka, Japan

Prevention of the renal scarring is quite important in the treatment of renal infection. We have been showing some antioxidants effective to prevent renal scar formation following renal infection due to bacteria harboring mannose-sensitive pili [1–3]. Dapsone is an old drug introduced for leprosy treatment, but is now being used in various situations such as dermal, vascular, arthral, alimentary disorders, and others. We think that dapsone has a strong anti-inflammatory effect on renal infection as well as other lesions through

mechanisms including direct inhibition of the functions of polymorphonuclear leukocytes (PMNs), effect on the arachidonic cascade, inhibition of oxygen species released from PMNs and others, and that it will possibly become the preventive drug for renal scarring following pyelonephritis. As in Dr. Wozel's comments, the preventive effect of dapsone on renal scarring may be due to an anti-inflammatory effect of dapsone itself or its metabolites. The mechanisms of action of dapsone in vivo should be further examined.

References

- 1 Haraoka M, Matsumoto T, Mizunoe Y, Takahashi K, Kubo S, Koikawa Y, Tanaka M, Sakamoto Y, Sakamoto M, Nagafuji T, Kumazawa J: Effect of Ebselen on renal scarring in rats following renal infection. *Chemotherapy* 1995;41:208–213.
- 2 Matsumoto T, Mizunoe Y, Sakamoto N, Kumazawa J: Suitability of colchicine and superoxide dismutase for the suppression of renal scarring following an infection with bacteria showing mannose-sensitive pili. *Nephron* 1990;56:130–135.
- 3 Matsumoto T, Mizunoe Y, Ogata N, Tanaka M, Takahashi K, Kumazawa J: Antioxidant effect on renal scarring following infection by MS-piliated bacteria. *Nephron* 1992;60:210–215.

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 1999 S. Karger AG, Basel
0009–3157/99/0453–0235\$17.50/0

Accessible online at:
<http://BioMedNet.com/karger>

Tetsuro Matsumoto, MD, PhD, Department of Urology, School of Medicine, University of Occupational and Environmental Health Japan 1-1, Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555 (Japan)
Tel. +81 93 691 7446, Fax +81 93 603 8724
E-Mail t-matsu@med.uoeh-u.ac.jp